Population Pharmacokinetics of Monalizumab in Patients with Advanced Solid Tumors.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2220
Abstract: Monalizumab is a novel, first-in-class humanized immunoglobulin G (IgG)-4 monoclonal antibody (mAb) immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. The objectives of this analysis were to develop a population pharmacokinetic (PK) model of… read more here.
Keywords: volume distribution; patients advanced; population pharmacokinetics; solid tumors ... See more keywords